Document is current

Article History

Received: 4 June 2024

Accepted: 14 September 2024

First Online: 23 September 2024

Declarations

:

: Informed consent was obtained from all individual participants included in the study.

: All procedures performed in studies involving human participants were in accordance with the ethical standard of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study design was approved by the Bern cantonal ethics committee (ClinicalTrials.gov: NCT04061213), conducted in accordance with the Declaration of Helsinki, and study participants provided written informed consent before any data collection.

: Dr. Bernhard reports a career development grant from the Swiss National Science Foundation. Dr. Pilgrim reports research grants to the institution from Biotronik, Boston Scientific and Edwards Lifesciences; speaker fees from Biotronik, Boston Scientific, Abbott, and Metronic; Clinical event committee for study sponsored by HighLifeSAS. Dr. Federico Caobelli reports ongoing Grants supports from Siemens Healthineers and from the University of Bern, as well as speaker honoraria from Bracco AG, Siemens AG and Pfizer AG, all for matters not related to the present study. Dr. Dobner reports a research grant for the Bern amyloidosis registry (B-CARE) (NCT04776824) and the ATTR Amyloidosis in Elderly Patients With Aortic Stenosis study (NCT04061213) on behalf of Inselspital Bern from Pfizer, and acknowledges speaker fees and travel grants unrelated to the submitted work from Boehringer Ingelheim, Alnylam and Pfizer. Dr. Windecker reports research, travel or educational grants to the institution from Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, V-Wave. Dr. Windecker serves as advisory board member and/or member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave and Xeltis with payments to the institution but no personal payments. He is also member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Dr. Stortecky reports research grants to the institution from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott, as well as personal fees from Boston Scientific, Teleflex and BTG. Dr. Gräni received research funding from the GAMBIT foundation for this work. Dr. Stortecky reports research grants to the institution from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott, as well as personal fees from Boston Scientific, Teleflex and BTG. Dr. Gräni further received funding from the Swiss National Science Foundation and Innosuisse, from the Center for Artificial Intelligence in Medicine Research Project Fund University Bern, outside of the submitted work. Dr. Bakula reports speaker fees and travel grants from Pfizer. Dr. Shiri reports speaker fees and travel grants from Alnylam Pharmaceuticals. Dr. Rominger and Dr. Caobelli are editors of European Journal of Nuclear Medicine and Molecular Imaging. All other authors report no conflicts. The remaining authors have nothing to disclose.